Who are Olmesartan medoxomil tablets low dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): High dose losartan, Valsartan Capsules, losartan/amlodpine, Diovan (Valsartan), Cozzar tablet, RAS Inhibitors.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olmesartan-medoxomil-tablets-low-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Olmesartan medoxomil tablets low dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Olmesartan medoxomil tablets low dose (Olmesartan medoxomil tablets low dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker (ARB). Area: Cardiovascular.

marketed Angiotensin II receptor blocker (ARB) AT1 receptor (Angiotensin II type 1 receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Olmesartan medoxomil tablets low dose (Olmesartan medoxomil tablets low dose) — Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company. Olmesartan medoxomil blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Olmesartan medoxomil tablets low dose TARGET	Olmesartan medoxomil tablets low dose	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
High dose losartan	High dose losartan	Baker Heart and Diabetes Institute	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Valsartan Capsules	Valsartan Capsules	Affiliated Hospital of Nantong University	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
losartan/amlodpine	losartan/amlodpine	University of Pavia	marketed	Angiotensin II receptor blocker (ARB) / Calcium channel blocker (CCB)	Angiotensin II receptors (AT1) and L-type calcium channels
Diovan (Valsartan)	Diovan (Valsartan)	Bayer	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)
Cozzar tablet	Cozzar tablet	Chong Kun Dang Pharmaceutical	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (angiotensin II type 1 receptor)
RAS Inhibitors	RAS Inhibitors	Shenzhen Second People's Hospital	marketed	ACE inhibitor or Angiotensin II receptor blocker (ARB)	ACE enzyme or Angiotensin II Type 1 receptor (AT1R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker (ARB) class)

Chong Kun Dang Pharmaceutical · 2 drugs in this class
Baker Heart and Diabetes Institute · 2 drugs in this class
Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
Lee's Pharmaceutical Limited · 2 drugs in this class
Bristol-Myers Squibb · 1 drug in this class
Guangdong Provincial People's Hospital · 1 drug in this class
Fifth Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
Bayer · 1 drug in this class
Arbor Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Olmesartan medoxomil tablets low dose — Competitive Intelligence Brief. https://druglandscape.com/ci/olmesartan-medoxomil-tablets-low-dose. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab